Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Royalty Pharma Plc Cl A (NQ: RPRX )

26.26 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 379
Open 26.26
Bid (Size) 26.44 (1)
Ask (Size) 26.60 (4)
Prev. Close 26.26
Today's Range 26.26 - 26.26
52wk Range 25.92 - 31.93
Shares Outstanding 388,132,400
Dividend Yield 3.05%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
Via Benzinga
June’s Biotech Boom: 3 Stocks to Buy for a Summertime Surge
Biotech surge alert! Discover three biotech stocks to buy as they catch up with the market in the rest of 2024. 
Via InvestorPlace

Performance

YTD
-7.11%
-7.11%
1 Month
-4.44%
-4.44%
3 Month
-13.65%
-13.65%
6 Month
-2.99%
-2.99%
1 Year
-16.40%
-16.40%

More News

Read More
Royalty Pharma to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma Announces Pricing of $1.5 Billion of Senior Unsecured Notes
From Royalty Pharma plc
Via GlobeNewswire
NASDAQ:RPRX: good value for what you're paying.
Via Chartmill
Looking Into Royalty Pharma's Recent Short Interest
Via Benzinga
NASDAQ:RPRX is an undervalued gem with solid fundamentals.
Via Chartmill
Why Is Agios Pharmaceuticals Stock Trading Higher On Tuesday?
Via Benzinga
Exposures Product Safety
Agios Pharmaceuticals Inks $905 Million Deal For Cancer Drug; Shares Poised To Break Out
Via Investor's Business Daily
Royalty Pharma and Agios Pharmaceuticals Enter Into Vorasidenib Royalty Agreement for $905 Million
From Royalty Pharma plc
Via GlobeNewswire
Heart Disease-Focused Cytokinetics Operations Are On Track Despite Acquisition Uncertainty, Analysts Observe
Via Benzinga
Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline
From Royalty Pharma plc; Cytokinetics
Via GlobeNewswire
7 Dividend Stocks to Buy at a 52-Week Low
Via InvestorPlace
Royalty Pharma to Present at Upcoming Investor Conferences
From Royalty Pharma plc
Via GlobeNewswire
RPRX Stock Earnings: Royalty Pharma Misses EPS, Misses Revenue for Q1 2024
Via InvestorPlace
Royalty Pharma Reports First Quarter 2024 Results
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma to Acquire Royalty Interest in Sanofi’s Frexalimab
From Royalty Pharma plc
Via GlobeNewswire
Amgen Reports Better-Than-Expected Q1 Results, $50M Milestone Payment
Via Benzinga
Royalty Pharma to Announce First Quarter 2024 Financial Results on May 9, 2024
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma Declares Second Quarter 2024 Dividend
From Royalty Pharma plc
Via GlobeNewswire
3 Pharma Stocks to Sell in April Before They Crash & Burn
Via InvestorPlace
Billionaire Bargain Bin: 3 Stocks the Forbes 400 Loves (That You’ve Never Heard Of)
Via InvestorPlace
April’s Hidden Gems: 3 Overlooked Stocks to Freshen Up Your Portfolio
Via InvestorPlace
The Healthcare Bargain Blitz: 7 Undervalued Stocks to Inject into Your Portfolio
Via InvestorPlace
For those who appreciate value investing, NASDAQ:RPRX is a compelling option with its solid fundamentals.
Via Chartmill
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.